Cargando…

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function

Interruption of the programmed death 1 (PD-1) / programmed death ligand 1 (PD-L1) pathway is an established and effective therapeutic strategy in human oncology and holds promise for veterinary oncology. We report the generation and characterization of monoclonal antibodies specific for canine PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Jin Wook, Withers, Sita S., Chang, Hong, Spanier, Justin A., De La Trinidad, Victoria L., Panesar, Harmanpreet, Fife, Brian T., Sciammas, Roger, Sparger, Ellen E., Moore, Peter F., Kent, Michael S., Rebhun, Robert B., McSorley, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332054/ https://www.ncbi.nlm.nih.gov/pubmed/32614928 http://dx.doi.org/10.1371/journal.pone.0235518

Ejemplares similares

Canine cancer immunotherapy studies: linking mouse and human
por: Park, Jiwon S., et al.
Publicado: (2016)

Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma
por: Minoli, Lucia, et al.
Publicado: (2022)

BMI1 Is Expressed in Canine Osteosarcoma and Contributes to Cell Growth and Chemotherapy Resistance
por: Shahi, Mehdi Hayat, et al.
Publicado: (2015)

Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro
por: Sirivisoot, Sirintra, et al.
Publicado: (2023)

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
por: Maekawa, Naoya, et al.
Publicado: (2016)

A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
por: Maekawa, Naoya, et al.
Publicado: (2017)

Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
por: Oh, Wonkyung, et al.
Publicado: (2023)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma
por: Sparger, Ellen E., et al.
Publicado: (2021)

Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
por: Aresu, Luca, et al.
Publicado: (2021)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

The Effect of Arginase on Canine T-Lymphocyte Functions and its Modulation by All-Trans Retinoid Acid (ATRA) in Canine Monocyte-Derived Macrophages
por: Soileau, Aimee M., et al.
Publicado: (2022)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

PD-1 pathway-mediated regulation of islet-specific CD4(+) T cell subsets in autoimmune diabetes
por: Martinov, Tijana, et al.
Publicado: (2016)

A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
por: Igase, Masaya, et al.
Publicado: (2020)

Quantification of pharmacokinetic profiles of a recombinant canine PD-1 fusion protein by validated sandwich ELISA method
por: Qiu, Jicheng, et al.
Publicado: (2022)

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
por: Ma, Li-Jie, et al.
Publicado: (2018)

PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4(+) T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes
por: Pauken, Kristen E., et al.
Publicado: (2013)

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
por: Ikeda, Sadakatsu, et al.
Publicado: (2016)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
por: Wang, Mingzhu, et al.
Publicado: (2019)

A monoclonal antibody-based sandwich ELISA for measuring canine Thymidine kinase 1 protein and its role as biomarker in canine lymphoma
por: Sharif, Hanan, et al.
Publicado: (2023)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

IQGAP1 is an oncogenic target in canine melanoma
por: Lee, Becky H., et al.
Publicado: (2017)

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
por: Fife, Brian T., et al.
Publicado: (2006)

Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance
por: Razmara, Aryana M., et al.
Publicado: (2021)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Evaluation of P16 expression in canine appendicular osteosarcoma
por: Murphy, B. G., et al.
Publicado: (2017)

PD-L1 gene amplification and focality: relationship with protein expression
por: Jardim, Denis Leonardo, et al.
Publicado: (2023)

Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report
por: Xu, Shuo, et al.
Publicado: (2023)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies
por: Al-Showbaki, Laith, et al.
Publicado: (2022)

Blocking Signaling at the Level of GLI Regulates Downstream Gene Expression and Inhibits Proliferation of Canine Osteosarcoma Cells
por: Shahi, Mehdi Hayat, et al.
Publicado: (2014)

Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis
por: Li, Han, et al.
Publicado: (2021)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o43866g1qi3b0if37c517lh666